A company that’s poised to disrupt the nasal drug delivery market has signed a licensing deal with Avanir Pharmaceuticals (Nasdaq: AVNR) valued at $110 million. OptiNose’s drug delivery system in ...
Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind's psychedelic-based treatments Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: ...
Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative ...
Hosted on MSN
New study validates insulin nasal spray to deliver Alzheimer's drug directly to the brain
A groundbreaking brain imaging study from Wake Forest University School of Medicine confirms a vital step toward new Alzheimer's disease treatments: Intranasal insulin, delivered via a simple nasal ...
DUBLIN--(BUSINESS WIRE)--The "Inhalation and Nasal Spray Generic Drugs - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Inhalation and ...
Clearmind Medicine (CMND) has signed a non-binding Letter of Intent with Polyrizon (PLRZ) to develop a novel intranasal formulation for its psychedelic-based treatment applications. The collaboration ...
Polyrizon Ltd., a biotech company based in Raanana, Israel, has announced the filing of a divisional patent application for its Trap & Target (T&T) platform technology with the Israel Patent Office.
SARASOTA, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today ...
Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results